LONA compared with IKT: revenue, margins and what each company keeps, and the suppliers and customers both name

LONALeonaBio, Inc.

Mkt capRevenueRevenue

IKTInhibikase Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

LONALeonaBio, Inc.

IKTInhibikase Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

LONA1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▼−3.20%—

IKT

Reportimpliedrealized× implied

Q2 FY26—▼−2.04%—

May 13 '26—▼−1.04%—

Q1 FY26

= impliedLONA realized, solidIKT realized, hatchedOne scale, both sides: full bar = 4%× = |realized| ÷ impliedSource: market data

—

▲+3.07%

—

Q3 FY25—▼−0.65%—

LONALeonaBio, Inc.

4.45▲+2.53%· post 4.45

Mkt cap$41.6MRevenue—

IKTInhibikase Therapeutics, Inc.

1.50▲+4.05%· post 1.50

ClosedNov 6 '26

Mkt cap$209.3MRevenue$79,569Q3 FY23

Compare

ClosedNov 6 '26

LONALeonaBio, Inc.

IKTInhibikase Therapeutics, Inc.

4.45▲+2.53%post 4.45

Price

1.50▲+4.05%post 1.50

$41.6M

Mkt cap

$209.3M

—

Revenue

$79,569Q3 FY23

LONA4.45▲+2.53%vsIKT1.50▲+4.05%ClosedNov 6 '26